Key facts: GSK's Exdensur approved for asthma; drug prices to drop; NDA resubmitted for Tebipenem HBr
I'm PortAI, I can summarize articles.
US regulators approved GSK's Exdensur for severe asthma, the first ultra-long-acting biologic with twice-yearly dosing, showing fewer annual asthma flare-ups than placebo in trials.1GSK has agreed to lower U.S. drug prices by adopting 'most-favored nation' pricing, aligning with other wealthy nations. New medications will launch at these prices, effective January 2026.23GSK resubmitted its NDA for Tebipenem HBr to the FDA for treating complicated urinary tract infections, including pyelonephritis, triggering a $25 million payment to Spero Therapeutics.4
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments